RxDoctor Payments Data

Peter Spencer, DO

Neurology · Saint Joseph, MINPI 1669479432

Payments from drug & device makers

$1,628in general payments, 2019–2025

Across 103 payments — averaging $15.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$538
  • Biogen$94
  • Johnson & Johnson$90
  • SK Life Science, Inc.$85
  • EMD Serono, Inc.$76
  • Lilly USA, LLC$61
  • plus $686 from 24 others

What the payments were for

  • Food & beverage$1,60999%
  • Education$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,628 in reported general payments places this provider in the 50th percentile of 652 neurology providers in Michigan.

See all neurology providers in Michigan

Medicare billing

Part B allowed, 2024
$72,850
Medicare patients
327
Services billed
1,128

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dimethyl Fumarate38$112,214
Kesimpta PenOfatumumab11$96,006
Glatiramer Acetate13$38,956
Aimovig AutoinjectorErenumab-Aooe32$32,340
Emgality PenGalcanezumab-Gnlm30$28,121
GlatopaGlatiramer Acetate11$19,357
BriviactBrivaracetam14$19,177
Nurtec OdtRimegepant Sulfate15$17,839
UbrelvyUbrogepant18$17,825
Levetiracetam308$15,668
Xtampza ErOxycodone Myristate12$14,263
Carbamazepine ErCarbamazepine64$13,098
FingolimodFingolimod Hcl25$10,648
Lacosamide95$9,935
Carbidopa-LevodopaCarbidopa/Levodopa226$9,155

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact$38$19,17714 claims
PfizerNurtec Odt$41$17,83915 claims
AbbVieUbrelvy$538$17,82518 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil$37$4,96361 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 652 neurology providers in Michigan.

Other neurology in Saint Joseph

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →